1. Home
  2. MYND vs BLRX Comparison

MYND vs BLRX Comparison

Compare MYND & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mynd.ai Inc.

MYND

Mynd.ai Inc.

HOLD

Current Price

$0.34

Market Cap

14.6M

Sector

Real Estate

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.31

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYND
BLRX
Founded
1998
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
12.6M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
MYND
BLRX
Price
$0.34
$2.31
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
6.7K
12.8K
Earning Date
05-05-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$2.15
52 Week High
$1.15
$7.77

Technical Indicators

Market Signals
Indicator
MYND
BLRX
Relative Strength Index (RSI) 43.42 41.47
Support Level $0.29 $2.15
Resistance Level $0.36 $2.51
Average True Range (ATR) 0.02 0.10
MACD 0.00 0.01
Stochastic Oscillator 66.39 22.39

Price Performance

Historical Comparison
MYND
BLRX

About MYND Mynd.ai Inc.

Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: